Author:
Tsang Chi Kwan,Qi Haiyan,Liu Leroy F.,Zheng X.F. Steven
Subject
Drug Discovery,Pharmacology
Reference103 articles.
1. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer;Yu;Endocr. Relat. Cancer,2001
2. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR;Neshat;Proc. Natl. Acad. Sci. U. S. A.,2001
3. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine;Schuurman;Transplantation,1997
4. mTOR-targeted therapy of cancer with rapamycin derivatives 10.1093/annonc/mdi113;Vignot;Ann. Oncol.,2005
5. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies;Mita;ASCO Meeting Abstracts,2004
Cited by
363 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献